These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 31534492)

  • 1. Characteristics and survival of older patients with metastatic pancreatic cancer: a retrospective analysis of the AC Camargo Cancer Center experience.
    Costa JG; de Jesus VHF; Camandaroba MPG; Dettino ALA
    Ther Adv Med Oncol; 2019; 11():1758835919874650. PubMed ID: 31534492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).
    Park HS; Kang B; Chon HJ; Im HS; Lee CK; Kim I; Kang MJ; Hwang JE; Bae WK; Cheon J; Park JO; Hong JY; Kang JH; Kim JH; Lim SH; Kim JW; Kim JW; Yoo C; Choi HJ
    ESMO Open; 2021 Apr; 6(2):100049. PubMed ID: 33578192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of efficacy and safety of Gemcitabine-based chemotherapy in patients with metastatic pancreatic adenocarcinoma experiencing disease progression on FOLFIRINOX.
    de Jesus VHF; Camandaroba MPG; Donadio MDS; Cabral A; Muniz TP; de Moura Leite L; Sant'Ana LF
    J Gastrointest Oncol; 2018 Oct; 9(5):806-819. PubMed ID: 30505579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
    Zahir MN; Jabbar AA
    Asian Pac J Cancer Prev; 2015; 16(14):6001-6. PubMed ID: 26320487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules.
    Foschini F; Napolitano F; Servetto A; Marciano R; Mozzillo E; Carratù AC; Santaniello A; De Placido P; Cascetta P; Butturini G; Frigerio I; Regi P; Silvestris N; Delcuratolo S; Vasile E; Vivaldi C; Bianco C; De Placido S; Formisano L; Bianco R
    Ther Adv Med Oncol; 2020; 12():1758835920947970. PubMed ID: 33062062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.
    Chevalier H; Vienot A; Lièvre A; Edeline J; El Hajbi F; Peugniez C; Vernerey D; Meurisse A; Hammel P; Neuzillet C; Borg C; Turpin A
    Oncologist; 2020 Nov; 25(11):e1701-e1710. PubMed ID: 32886823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia.
    Body A; Wong R; Shapiro J; Jalali A; McLachlan SA; Ananda S; Lipton L; Cooray P; Gibbs P; Lee B; Lee M
    Intern Med J; 2022 Jan; 52(1):49-56. PubMed ID: 33040452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
    Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
    Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    Sohal DP; Mangu PB; Khorana AA; Shah MA; Philip PA; O'Reilly EM; Uronis HE; Ramanathan RK; Crane CH; Engebretson A; Ruggiero JT; Copur MS; Lau M; Urba S; Laheru D
    J Clin Oncol; 2016 Aug; 34(23):2784-96. PubMed ID: 27247222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
    Bonnet E; Mastier C; Lardy-Cléaud A; Rochefort P; Sarabi M; Guibert P; Cattey-Javouhey A; Desseigne F; de La Fouchardière C
    Curr Oncol; 2019 Aug; 26(4):e466-e472. PubMed ID: 31548814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single center experience.
    Cavanna L; Stroppa EM; Citterio C; Mordenti P; Di Nunzio C; Peveri S; Orlandi E; Vecchia S
    Onco Targets Ther; 2019; 12():3077-3085. PubMed ID: 31118666
    [No Abstract]   [Full Text] [Related]  

  • 12. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
    Kobayashi N; Omae K; Horita Y; Ueno H; Mizuno N; Uesugi K; Sudo K; Ozaka M; Hayashi H; Okano N; Kamei K; Yamaguchi A; Kobayashi S; Suzuki S; Ishihara S; Uchiyama T; Todaka A; Fukutomi A
    Pancreatology; 2020 Oct; 20(7):1519-1525. PubMed ID: 32972834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older.
    Mizrahi JD; Rogers JE; Hess KR; Wolff RA; Varadhachary GR; Javle MM; Shroff RT; Ho L; Fogelman DR; Raghav KPS; Overman MJ; Pant S
    Pancreatology; 2020 Apr; 20(3):501-504. PubMed ID: 31932214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.
    Muranaka T; Kuwatani M; Komatsu Y; Sawada K; Nakatsumi H; Kawamoto Y; Yuki S; Kubota Y; Kubo K; Kawahata S; Kawakubo K; Kawakami H; Sakamoto N
    J Gastrointest Oncol; 2017 Jun; 8(3):566-571. PubMed ID: 28736643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions.
    Lambert A; Gavoille C; Conroy T
    Therap Adv Gastroenterol; 2017 Aug; 10(8):631-645. PubMed ID: 28835777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes with First-Line Chemotherapy in a Large Retrospective Study of Patients with Metastatic Pancreatic Cancer Treated in a US Community Oncology Setting.
    Cartwright TH; Parisi M; Espirito JL; Wilson TW; Pelletier C; Patel M; Babiker HM
    Drugs Real World Outcomes; 2018 Sep; 5(3):149-159. PubMed ID: 29946913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
    Matsumoto I; Kamei K; Omae K; Suzuki S; Matsuoka H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi M; Todaka A; Fukutomi A
    Pancreatology; 2019 Mar; 19(2):296-301. PubMed ID: 30638853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Toxicity of Different Chemotherapy Regimens in the Treatment of Advanced or Metastatic Pancreatic Cancer: A Network Meta-Analysis.
    Liu GF; Li GJ; Zhao H
    J Cell Biochem; 2018 Jan; 119(1):511-523. PubMed ID: 28608558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy.
    Lee HS; Kim SY; Chung MJ; Park JY; Bang S; Park SW; Song SY
    Nutr Cancer; 2019; 71(7):1100-1107. PubMed ID: 30955349
    [No Abstract]   [Full Text] [Related]  

  • 20. Pancreatic Cancer: A Retrospective Study From the Najran Region of Saudi Arabia.
    Badheeb AM; Awad MA; Al Masad AG; Alyami MS; Fagihi MA; Al Walani M; Alkarak S; Al Bahili HM; Alatawi A; Nagi NM; Madbouly AR; Abu Bakar A; Ahmed F; Badheeb M
    Cureus; 2024 Jul; 16(7):e65685. PubMed ID: 39205701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.